| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA676: Filgotinib for treating moderate to severe rheumatoid arthritis |
|
Medicine details |
|
| Medicine name | filgotinib (Jyseleca®) |
| Formulation | 100mg, 200mg film coated tablets |
| Reference number | 3208 |
| Indication | Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX) |
| Company | Gilead Sciences Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/09/2020 |
| NICE guidance | TA676: Filgotinib for treating moderate to severe rheumatoid arthritis |